drugset / Trial / NCT01479192

Fenretinide in Healthy Young Women at Genetic and Familial Risk

NCT01479192

Phase 3 Terminated 20 enrolled European Institute of Oncology
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this trial is to assess the effect of fenretinide (4-HPR), a vitamin A derivative, in reducing the incidence of breast cancer in healthy premenopausal women at increased familial/genetic risk for breast cancer

Timeline

Start
2009-12
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject fenretinide Small molecule 100 mg